The third quarter of 2025 closed amid growing macroeconomic strain, policy unpredictability and renewed investor focus on execution risk. While ...

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat ...